Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual COVID-19 and influenza vaccines
NCT06355232Phase 1Recruiting
- Sponsor
- Vaxine
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SpikoGen in coronavirus disease 2019 (COVID-19) and influenza (3 arms), sponsored by Vaxine. Primary endpoints: SARS-CoV-2 Seroconversion at 2 weeks, Influenza Seroconversion at 2 weeks and 7 more. Started May 2024; status: recruiting.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06355232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355232.